Petros pharmaceuticals' stendra(r) (avanafil) pivotal consumer self-selection study for over-the-counter access demonstrates statistical significance

Vital study aligned with fda guidelines shows encouraging performance as petros continues close fda contact for a potential technology-centered rx-to-otc switch new york, ny / accesswire / july 16, 2024 / petros pharmaceuticals, inc. (nasdaq:ptpi) ("petros" or the "company"), a company focused on expanding consumer access to medication through over-the-counter ("otc") drug development programs, announces results of the first of a series of pivotal studies aimed at facilitating fda-approved otc access of stendra® (avanafil) for consumers. the pivotal self-selection study showed that consumers who used the company's proprietary web app technology, designed to assist in the appropriate consumer self-selection for receiving the drug, had a statistically significant (p
PTPI Ratings Summary
PTPI Quant Ranking